Árpád Molnár

Prof. Árpád Molnár


Research Focus & Metrics

Academic Career Length

52Years (1975-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 September 2001 in Journal of Molecular Catalysis A: Chemical
Verified
Journal Article
Closed access
Árpád MolnárÁrpád Molnár
Árpád Molnár
ASAntal Sárkány
Antal Sárkány
MVMónika Varga
Mónika Varga

19 June 2008
Verified
Book
Open access
GOGeorge A. Olah
George A. Olah
GPG. K. Surya Prakash
G. K. Surya Prakash
Árpád MolnárÁrpád Molnár
Árpád Molnár
JSJean Sommer
Jean Sommer
Click on the title to browse this book

18 April 2003
Verified
Book
Open access
GOGeorge A. Olah
George A. Olah
Árpád MolnárÁrpád Molnár
Árpád Molnár
Click on the title to browse this book

1 July 2007 in Tetrahedron
Verified
Journal Article
Closed access
VPVivek Polshettiwar
Vivek Polshettiwar
Árpád MolnárÁrpád Molnár
Árpád Molnár

1 May 1997 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
Árpád MolnárÁrpád Molnár
Árpád Molnár
ATAnne M. Theodoras
Anne M. Theodoras
LZLeonard I. Zon
Leonard I. Zon
JKJohn M. Kyriakis
John M. Kyriakis
Antimitogenic stimuli such as environmental or genotoxic stress, transforming growth factor-β, and the inflammatory cytokines tumor necrosis factor and interleukin-1 activate two extracellular signal-regulated kinase (ERK)-based signaling pathways: the stress-activated protein kinase (SAPK/JNK) pathway and the p38 pathway. Activated p38 phosphorylates transcription factors important in the regulation of cell growth and apoptosis, including activating transcription factor 2 (ATF2), Max, cAMP response element-binding protein-homologous protein/growth arrest DNA damage 153 (CHDP/GADD153). In turn, p38 lies downstream of the Rho family GTPases Cdc42Hs and Rac1, as well as at least three mitogen-activated protein kinase (MAPK)/ERK-kinases (MEKs): MAPK kinases-3, -6, and SAPK/ERK-kinase-1. Although many of the stimuli that activate p38 can also inhibit cell cycle progression, a clear-cut role for the p38 pathway in cell cycle regulation has not been established. Using a quantitative microinjection approach, we show here that Cdc42Hs, but not Rac1 or RhoA, can inhibit cell cycle progression at G1/S through a mechanism requiring activation of p38. These results suggest a novel role for Cdc42Hs in cell cycle inhibition. Furthermore, these results suggest that although both Cdc42Hs and Rac1 can activate p38in situ, the effects of Cdc42Hs and Rac1 on cell cycle progression are, in fact, quite distinct.